Alternative compounded versions of Novo Nordisk’s blockbuster weight-loss and diabetes drugs have hurt its sales, ...

About a dozen lawsuits, citing 2024 studies, allege Ozempic causes a rare eye disorder that leads to irreversible blindness. ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

A new generation of GLP-1 drugs promising fast results continues to rock the weight loss industry, which has emphasized ...

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...

A grandma of 11 and a New Jersey man have joined the growing chorus of users of the wildly popular weight-loss drugs Ozempic ...

A federal court judge ruling leaves in place an FDA determination that shortages of the Novo Nordisk drugs Wegovy and Ozempic ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...

Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...

Novo Nordisk has slashed its full-year revenue and profit forecasts for the first time since launching its blockbuster weight ...